EUCTR2005-002759-42-DE进行中（未招募）不适用
A Randomized, Double-Blind, Multicenter, Multinational, Placebo-Controlled Study of the Safety, Efficacy, and Pharmacokinetics of Myozyme, Recombinant Human Acid alpha-Glucosidase (rhGAA), Treatment in Patients with Late-Onset Pompe Disease - LOTS
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 90
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. The patient must provide signed, informed consent prior to performing any study-related procedures. Consent of a legally authorized guardian(s) is (are) required for patients under 18 years of age. If the patient is under 18 years of age and can understand the written informed consent, signature will be required from both the patient and the authorized guardian(s); 2. The patient must have a diagnosis of Pompe disease based on deficient endogenous GAA activity in cultured skin fibroblasts of = 40% of the normal mean of the testing laboratory and 2 confirmed GAA gene mutations; 3. The patient must be = 8 years of age at the time of enrollment; 4. The patient must have muscle weakness in the lower limbs based on unilateral QMT of the knee extensors defined as < 80% of the predicted value based on age, gender and body size (The National Isometric Muscle Strength [NIMS] Database Consortium, 1996, Arch Phys Med Rehabil); 5. The patient must be able to tolerate pulmonary function testing (PFT) and muscle testing in the supine position. (See exclusion criteria [1] and [2].); 6. The patient must be able to provide reproducible muscle and pulmonary function test results (bilateral
- •QMT measurements [% predicted] in knee extensors within 10% of the highest test value obtained from the same side of the body on 2 consecutive days and FVC measurements [in liters] within 10% of the highest test value obtained in the upright position on 2 consecutive days); 7. The patient must have an FVC of = 30% and < 80% predicted in the upright position (American Thoracic Society [ATS], 1991, Am Rev Respir Disease); 8. The patient must have an FEV1/FVC value of = 70% predicted in the upright position (ATS, 1991, Am Rev Respir Disease); 9. The patient must have a postural drop in FVC (liters) of at least 10% from the upright to the supine position [(FVC supine (L) – FVC upright (L))/FVC upright (L)] * 100%; 10. The patient must have testable muscle in bilateral knee flexors and knee extensors, and testable muscle in bilateral elbow flexors and elbow extensors. (Using QMT, a muscle will be defined as not testable” if the patient: 1) has a contracture > 90 degrees that would keep them from being able to assume the standard testing position, 2) is unable to follow directions, 3) has significant pain with resistance to the motion, or 4) is so weak that force cannot be generated against the testing strap); 11. The patient must be able to ambulate 40 meters (approximately 130 feet) in 6 minutes on each of 2 consecutive tests performed on the same day (use of assistive devices such as a walker, cane, or crutches, is permitted); 12. The patient (and patient’s legal guardian if patient <18 years of age) must have the ability to comply with the clinical protocol; 13. A female patient of childbearing potential must have a negative pregnancy test (urine beta-human chorionic gonadotropin [ß-hCG]) at Baseline. Note: All female patients of childbearing potential and sexually mature males must use a medically accepted method of contraception throughout the study.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. The patient requires the use of invasive ventilatory support. (Invasive ventilation is defined as any form of ventilatory support applied with the use of an endotracheal tube.); 2. The patient requires the use of noninvasive ventilatory support while awake and in an upright position. (Noninvasive ventilation is defined as any form of ventilatory support applied without the use of an endotracheal tube. For example, patients receiving positive-pressure ventilation support through a facemask or nose piece are considered as ventilated through noninvasive methods.); 3. The patient has received enzyme replacement therapy with GAA from any source; 4. The patient has used an investigational product within 30 days prior to study enrollment, or is currently enrolled in another study which involves clinical evaluations, unless prior approval is given by Genzyme; 5. The patient has a medical condition, serious intercurrent illness, or other extenuating circumstance that, in the opinion of the Investigator, may significantly interfere with study compliance, including all prescribed evaluations and follow-up activities; 6. The patient has a major congenital anomaly.
研究者
相似试验
Unknown
3 期
A study to compare the efficacy and safety of INTP24 against Avastin® in patients with lung cancer.CTRI/2019/08/020665Intas Pharmaceuticals Ltd Biopharma Division32
进行中（未招募）
不适用
A Study to Evaluate the Efficacy and Safety of PEGylated Interferon Beta-1a (BIIB017) in Subjects with Relapsing Multiple SclerosisRelapsing Multiple SclerosisMedDRA version: 16.0Level: PTClassification code 10028245Term: Multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersEUCTR2008-006333-27-CZBiogen Idec Limited1,500
Unknown
2 期
A Study to Evaluate the Effectiveness and Safety of Etrasimod in the Treatment of Active Crohnâ??s DiseaseCTRI/2020/12/029571Arena Pharmaceuticals
进行中（未招募）
1 期
A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Assess the Efficacy and Safety of 12 Week Treatment with Vildagliptin (LAF237) 50 mg QD in Subjects with Impaired Glucose Tolerance (IGT)Type II DiabetesEUCTR2005-002778-30-FIovartis Pharma Services AG
进行中（未招募）
不适用
A Multicenter, Randomized, Double-Blind, Parallel-Group, Active-Control, Dose-Ranging Study to Evaluate the Safety, Efficacy, and Comparative Systemic Bioavailability of a Single Administration of SKY0402 via Local Infiltration for Prolonged Postoperative Analgesia in Subjects Undergoing Total Knee Arthroplastypost-operative pain managementEUCTR2007-005115-26-ATPacira Pharmaceuticals Inc.100